Pfizer Net Income From Continuing Ops from 2010 to 2024

PFE Stock   11.94  0.26  2.23%   
Pfizer Net Income From Continuing Ops yearly trend continues to be very stable with very little volatility. Net Income From Continuing Ops is likely to drop to about 2.1 B. During the period from 2010 to 2024, Pfizer Net Income From Continuing Ops quarterly data regression pattern had sample variance of 52155086.9 T and median of  11,179,000,000. View All Fundamentals
 
Net Income From Continuing Ops  
First Reported
2010-12-31
Previous Quarter
2.2 B
Current Value
2.1 B
Quarterly Volatility
7.2 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Pfizer financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Pfizer's main balance sheet or income statement drivers, such as Interest Income of 1.7 B, Discontinued Operations of 5.1 M or Interest Expense of 1.7 B, as well as many indicators such as . Pfizer financial statements analysis is a perfect complement when working with Pfizer Valuation or Volatility modules.
  
This module can also supplement various Pfizer Technical models . Check out the analysis of Pfizer Correlation against competitors.

Pair Trading with Pfizer

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Pfizer position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Pfizer will appreciate offsetting losses from the drop in the long position's value.

Moving against Pfizer Stock

  0.73TD-PFI Toronto Dominion BankPairCorr
  0.66AMZN Amazon CDRPairCorr
  0.63BNS Bank of Nova ScotiaPairCorr
  0.6BMO Bank of MontrealPairCorr
  0.45RY Royal BankPairCorr
The ability to find closely correlated positions to Pfizer could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Pfizer when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Pfizer - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Pfizer Inc CDR to buy it.
The correlation of Pfizer is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Pfizer moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Pfizer Inc CDR moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Pfizer can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Other Information on Investing in Pfizer Stock

Pfizer financial ratios help investors to determine whether Pfizer Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Pfizer with respect to the benefits of owning Pfizer security.